BioMarin is a global pharmaceutical company focused on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. These conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options and are usually ignored. Time is critical to patients with rare diseases, and BioMarin strive to quickly develop important therapies for them.

The Company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® for mucopolysaccharidosis VI; Aldurazyme® for mucopolysaccharidosis I; and Kuvan® Tablets, for phenylketonuria.

TypePublic
HQSan Rafael, US
Founded1997
Size (employees)2,293 (est)
Websitebiomarin.com
BioMarin Pharmaceutical was founded in 1997 and is headquartered in San Rafael, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

BioMarin Pharmaceutical Office Locations

BioMarin Pharmaceutical has offices in Indianapolis, New York, Nashville, Taipei and in 29 other locations
San Rafael, US (HQ)
770 Lindaro St
Novato, US
105 Digital Dr
Mocoa, CO
96 Cra. 9
Kronberg im Taunus, DE
28 Westerbachstraße
Hong Kong, HK
Mass Mutual Tower 38 Gloucester Rd
Dublin, IE
Saint James House Adelaide Rd
Show all (34)
Report incorrect company information

BioMarin Pharmaceutical Financials and Metrics

BioMarin Pharmaceutical Revenue

Embed Graph
BioMarin Pharmaceutical's revenue was reported to be $1.12 b in FY, 2016 which is a 25.5% increase from the previous period.
USD

Revenue (Q2, 2018)

746.3m

Gross profit (Q2, 2018)

584.9m

Gross profit margin (Q2, 2018), %

78.4%

Net income (Q2, 2018)

(60.9m)

EBIT (Q2, 2018)

(69.6m)

Market capitalization (15-Oct-2018)

17.7b

Closing stock price (15-Oct-2018)

99.5

Cash (30-Jun-2018)

427.4m
BioMarin Pharmaceutical's current market capitalization is $17.7 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

548.5m751.0m889.9m1.1b

Revenue growth, %

37%18%26%

Cost of goods sold

95.7m129.8m152.0m209.6m

Gross profit

452.7m621.3m737.9m907.2m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Revenue

136.9m151.6m191.8m176.8m203.3m250.5m208.9m236.7m300.0m279.9m303.7m317.4m334.1m373.4m746.3m

Cost of goods sold

28.1m22.8m31.2m29.9m32.8m39.9m36.7m43.1m51.6m50.7m50.0m56.3m59.5m82.3m161.4m

Gross profit

108.8m128.7m160.6m146.9m170.5m210.6m172.2m193.6m248.4m229.2m253.7m261.1m274.7m291.1m584.9m

Gross profit Margin, %

80%85%84%83%84%84%82%82%83%82%84%82%82%78%78%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

568.8m875.5m397.0m408.3m

Accounts Receivable

117.8m144.5m165.0m215.3m

Inventories

162.6m199.5m271.7m355.1m

Current Assets

1.1b1.4b1.1b1.4b
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Cash

181.6m639.8m584.7m398.0m900.6m440.7m376.3m270.5m306.0m707.3m348.2m354.9m431.4m474.0m427.4m

Accounts Receivable

124.7m110.5m122.3m121.4m175.7m186.1m148.9m180.8m214.2m215.9m230.3m238.3m251.9m318.4m363.6m

Inventories

148.7m176.9m193.5m204.4m222.8m237.5m262.1m297.0m326.6m347.4m384.1m429.8m457.4m468.2m473.4m

Current Assets

713.5m1.2b1.2b1.1b1.5b1.2b1.2b992.8m1.1b1.7b1.4b1.5b2.1b2.2b2.3b
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(176.4m)(134.0m)(171.8m)(630.2m)

Depreciation and Amortization

47.3m56.7m47.2m96.9m

Inventories

(34.0m)(37.0m)(51.0m)(64.5m)

Cash From Operating Activities

(59.6m)(73.5m)(221.7m)(227.8m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018Q2, 2018

Net Income

(53.0m)(38.1m)(33.5m)7.4m(67.5m)(82.0m)(90.9m)(85.1m)(424.0b)(42.8m)(16.3m)(44.1m)(60.9m)

Depreciation and Amortization

23.6m44.6m

Inventories

193.5m204.4m222.8m237.5m262.1m297.0m326.6m347.4m384.1m10.8m15.5m

Accounts Payable

(51.9m)(33.0m)
USDY, 2018

Financial Leverage

1.6 x
Show all financial metrics

BioMarin Pharmaceutical Operating Metrics

FY, 2016

Patent Applications

426

Patents Issued

1.17 k

Phase 1/2 Trials Products

2

Phase III Trials Products

2
Show all operating metrics

BioMarin Pharmaceutical Revenue Breakdown

Embed Graph

BioMarin Pharmaceutical revenue breakdown by geographic segment: 18.4% from Rest of the World , 13.3% from Latin America, 22.7% from Europe and 45.5% from United States

Report incorrect company information

BioMarin Pharmaceutical News and Updates

Report incorrect company information

BioMarin Pharmaceutical Blogs

BioMarin and Believe Limited Announce Selection of 25 High School Students to Perform in First-of-its-Kind 'Hemophilia: The Musical'

The young adults, each affected by a bleeding disorder, will perform in the Broadway-style musical upon completion of the 'Breaking Through!' Musical Theater Intensive workshop

Forbes Names BioMarin Among World's Best Employers

Company listed amongst top five biotech employers

BioMarin to Participate in Two Investor Conferences in October

Cantor Fitzgerald Global Healthcare Conference on October 1 in New York City

BioMarin to Participate in Three Investor Conferences in September

- Citi's 13th Annual Biotech Conference on September 5-6 in Boston

BioMarin Pharmaceutical Company Life and Culture

Report incorrect company information